drugset / Trial / NCT00160433

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.

NCT00160433

Phase 2 Completed 131 enrolled Abbott Jenapharm GmbH & Co. KG · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to determine the safety and efficacy of 3 asoprisnil doses (0.5 mg, 1.5 mg, and 5.0 mg) for 12 weeks in women with endometriosis.

Timeline

Start
2002-08
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 0.5 mg Oral
Subject Asoprisnil Other / unclassified 1.5 mg Oral
Subject Asoprisnil Other / unclassified 5 mg Oral

Indications